Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Pharmaceuticals Année : 2023

Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases

Quentin Delbaere
Nicolas Chapet
  • Fonction : Auteur
Fabien Huet
Clément Delmas
Nathan Mewton
  • Fonction : Auteur
Fabrice Prunier
  • Fonction : Auteur
Denis Angoulvant

Résumé

Incidence and mortality rates for cardiovascular disease are declining, but it still remains a major cause of morbidity and mortality. Drug treatments to slow the progression of atherosclerosis focus on reducing cholesterol levels. The paradigm shift to consider atherosclerosis an inflammatory disease by itself has led to the development of new treatments. In this article, we discuss the pathophysiology of inflammation and focus attention on therapeutics targeting different inflammatory pathways of atherosclerosis and myocardial infarction. In atherosclerosis, colchicine is included in new recommendations, and eight randomized clinical trials are testing new drugs in different inflammatory pathways. After a myocardial infarction, no drug has shown a significant benefit, but we present four randomized clinical trials with new treatments targeting inflammation.
Fichier principal
Vignette du fichier
2023 Delbaere et al., Anti.pdf (325.42 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03951833 , version 1 (24-01-2023)

Identifiants

Citer

Quentin Delbaere, Nicolas Chapet, Fabien Huet, Clément Delmas, Nathan Mewton, et al.. Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases. Pharmaceuticals, 2023, 16 (1), pp.78. ⟨10.3390/ph16010078⟩. ⟨hal-03951833⟩
19 Consultations
24 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More